Home › Funds › Cormorant Asset Management, LP › BBOT
Cormorant Asset Management, LP position in BBOT
BRIDGEBIO ONCOLOGY THERAPEUT · Health Care
Cormorant Asset Management, LP reported holding 17,878,594 shares of BBOT (BRIDGEBIO ONCOLOGY THERAPEUT) in its Q3 2026 13F filing — a position valued at US$73.3M, representing 5.24% of its reported portfolio and ranking #5 among its reported holdings. Cormorant Asset Management, LP has disclosed BBOT holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's BBOT position evolved
Cormorant Asset Management, LP first disclosed a stake in BBOT in Q3 2025 at 17,878,594 shares (US$207.0M). The position peaked in Q4 2025 at 17,878,594 shares, worth US$223.8M. Across 5 filings, Cormorant Asset Management, LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 17,878,594 shares valued at US$73.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 17.88M | $207.03M | New |
| Q4 2025 | 17.88M | $223.84M | Hold |
| Q1 2026 | 17.88M | $160.01M | Hold |
| Q2 2026 | 17.88M | $136.23M | Hold |
| Q3 2026 | 17.88M | $73.30M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBOT and 13F data
BBOT (BRIDGEBIO ONCOLOGY THERAPEUT) is a Health Care company. 87 other funds we track also report a position in BBOT — the largest reported positions include Omega Fund Management, LLC (US$13.5M), Alphabet Inc. (US$11.6M), Enavate Sciences GP, LLC (US$10.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBOT
- Omega Fund Management, LLC 3.29M sh · $13.49M · Q3 2026
- Alphabet Inc. 2.82M sh · $11.57M · Q3 2026
- Enavate Sciences GP, LLC 2.63M sh · $10.77M · Q3 2026
- REGENTS OF THE UNIVERSITY OF CALIFORNIA 2.51M sh · $10.29M · Q3 2026
- Novo Holdings A/S 2.25M sh · $9.22M · Q3 2026
- Opaleye Management Inc. 700.00K sh · $5.33M · Q2 2026
- Aisling Capital Management LP 1.02M sh · $4.14M · Q3 2026
- EcoR1 Capital, LLC 889.61K sh · $3.65M · Q3 2026
- Catalio Capital Management, LP 699.53K sh · $2.87M · Q3 2026
- Casdin Capital 282.31K sh · $1.16M · Q3 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held BBOT?
Cormorant Asset Management, LP has disclosed BBOT holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Cormorant Asset Management, LP's current position in BBOT?
As of Q3 2026, Cormorant Asset Management, LP holds 17.88M shares of BBOT (BRIDGEBIO ONCOLOGY THERAPEUT), valued at $73.30M, representing 5.24% of its reported portfolio and ranking #5.
Has Cormorant Asset Management, LP been buying or selling BBOT?
In the latest 13F filing (Q3 2026), Cormorant Asset Management, LP held unchanged its position in BBOT. The position peaked in Q4 2025 at 17.88M shares.
Which other funds hold BBOT?
Other major institutional holders of BBOT include Omega Fund Management, LLC, Alphabet Inc., Enavate Sciences GP, LLC, among 87 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.